New York-based PreciseDx is making waves in the field of breast cancer recurrence prediction with its innovative AI technology. After securing a significant $20.7 million Series B funding, the physicians-founded startup is on a mission to revolutionize the way breast cancer patients are diagnosed and treated.
The Power of AI in Predicting Breast Cancer Recurrence
At the core of PreciseDx’s advancements lies PreciseBreast, a cutting-edge tool that leverages a custom AI model to analyze millions of data points specific to breast cancer patients. By combining this AI technology with its proprietary morphology feature array, PreciseBreast can accurately assess the risk of recurrence in early-stage breast cancer patients, providing them with crucial information about their future health prospects.
One of the key benefits of PreciseBreast is its ability to generate a “recurrence score” that complements existing markers like HER2, a known indicator of breast cancer. By incorporating this additional data point into the diagnostic process, healthcare professionals can gain a more comprehensive understanding of a patient’s individual risk profile, enabling them to tailor treatment plans more effectively.
Validation Studies and Clinical Impact
A recent analytical validation study published in “Clinical Breast Cancer” demonstrated the high accuracy of PreciseBreast in predicting the risk of recurrence in early-stage breast cancer patients within a six-year timeframe. This milestone achievement underscores the potential of AI-driven technologies to enhance the standard of care for breast cancer patients worldwide.
Dr. Michael Donovan, co-founder and chief medical officer of PreciseDx, emphasized the significance of these results in empowering both individuals and healthcare professionals with advanced tools for managing breast cancer. He highlighted the role of PreciseBreast in improving accessibility and standardization in breast cancer care, ultimately leading to better outcomes for patients across the globe.
Collaboration with UCLA and Future Prospects
In a strategic move to further validate the effectiveness of PreciseBreast, PreciseDx partnered with UCLA’s Department of Pathology and Laboratory Medicine to assess the tool’s ability to predict recurrence risks in patients diagnosed with triple-negative breast cancer. This aggressive form of the disease presents unique challenges due to its association with younger women, BRCA1/2 gene mutations, and ethnic/racial disparities.
PreciseBreast boasts several advantages, including enhanced accuracy, reduced costs, and expedited results delivery within 48 hours. Moreover, the tool meets stringent regulatory standards such as the Clinical Laboratory Improvement Amendments (CLIA) and has received validation from the Clinical Laboratory Evaluation Program (CLEP) of the New York State Department of Health. With the latest round of funding, PreciseDx aims to expand the commercialization efforts for PreciseBreast, ensuring broader access to this groundbreaking technology.
The Visionary Team Behind PreciseDx
Founded in 2019 by a team of distinguished physicians, PreciseDx is led by a group of visionary leaders with extensive experience in healthcare and biotechnology. Dr. Carlos Cordon-Cardo, chair of the company’s advisory board, brings a wealth of knowledge from his tenure at the Icahn School of Medicine at Mount Sinai Health System and Memorial Sloan-Kettering Cancer Center.
Dr. Michael Donovan, vice chair and professor of Translational Research at the University of Miami, has a rich background in academic research and biotechnology, having held senior positions at Millennium Pharmaceuticals and Incyte Pharmaceuticals. His commitment to advancing precision medicine is reflected in PreciseDx’s mission to transform breast cancer management through AI-driven solutions.
Jack Zeineh, chief technology officer of PreciseDx, brings a strong technical expertise from his previous roles at Clarient, Carl Zeiss Microimaging AIS, and Aureon Biosciences. His academic achievements in Biological Sciences and medical training from the University of California at San Diego underscore his dedication to innovation in healthcare technology.
Dr. Gerardo Fernandez, chief scientific officer at PreciseDx, holds an adjunct associate professorship at the Icahn School of Medicine at Mount Sinai Health System. With a background in surgical pathology and cytopathology, Dr. Fernandez contributes valuable insights to the development of PreciseDx’s diagnostic solutions.
Driving Innovation in Healthcare
As CEO of PreciseDx, Eric Converse brings a wealth of experience in the healthcare industry, having previously led AMRA Medical AB, a Software-as-a-Medical Device (SaMD) company backed by Pfizer Ventures and Novo Holdings. His strategic vision and leadership skills are instrumental in guiding PreciseDx towards commercial success and broader adoption of its AI-driven technologies.
The collaborative efforts of the PreciseDx team, coupled with their dedication to advancing precision medicine in breast cancer care, position the company as a leading innovator in the field. By harnessing the power of AI and data analytics, PreciseDx is paving the way for personalized, targeted treatments that can significantly improve outcomes for breast cancer patients.
In conclusion, PreciseDx’s pioneering approach to predicting breast cancer recurrence with AI technology represents a significant step forward in the fight against this devastating disease. With their innovative tools and visionary team, PreciseDx is poised to make a lasting impact on the field of oncology and improve the lives of countless individuals affected by breast cancer.